These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 342317

  • 1. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers.
    Hrabar A, Vodopija I, André FE, Mitchell JR, Maassab HF, Hennessy AV, Davenport FM.
    Dev Biol Stand; ; 39():53-60. PubMed ID: 342317
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH, Seo SU, Song JM, Lee CM, Kim HA, Seong BL.
    Vaccine; 2006 Mar 10; 24(11):1966-74. PubMed ID: 16343703
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials with a new influenza subunit vaccine in adults and children.
    Kunz C, Hofmann H, Bachmayer H, Liehl E, Moritz AJ.
    Dev Biol Stand; 2006 Mar 10; 39():297-302. PubMed ID: 342311
    [Abstract] [Full Text] [Related]

  • 5. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB.
    J Infect Dis; 2001 Jan 15; 183(2):329-332. PubMed ID: 11110645
    [Abstract] [Full Text] [Related]

  • 6. Attenuation of influenza A/New Jersey/76 virus strain, preparation of live vaccine and vaccine reactogenicity in volunteers.
    Ikić D, Pasini N, Hećimović M, Juzbasić M, Smerdel S, Rajner N, Jelavić V.
    Dev Biol Stand; 2001 Jan 15; 39():61-5. PubMed ID: 342318
    [Abstract] [Full Text] [Related]

  • 7. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB.
    J Infect Dis; 2006 Nov 15; 194(10):1394-7. PubMed ID: 17054068
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Aug 27; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 13. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M.
    J Infect Dis; 2000 Mar 15; 181(3):1133-7. PubMed ID: 10720541
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, Lambert JS, Belshe RB.
    J Infect Dis; 2000 Feb 15; 181(2):725-8. PubMed ID: 10669363
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.
    Pediatrics; 2008 Mar 15; 121(3):e568-73. PubMed ID: 18299305
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 15; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 18. Biological, genetic and biochemical characterization of a cold-adapted recombinant A/Victoria/3/75 virus and its evaluation in volunteers.
    Maassab HF, Cox NJ, Murphy BR, Kendal AP.
    Dev Biol Stand; 2006 Sep 15; 39():25-31. PubMed ID: 604106
    [Abstract] [Full Text] [Related]

  • 19. Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.
    Cate TR, Couch RB.
    Infect Immun; 1982 Oct 15; 38(1):141-6. PubMed ID: 7141686
    [Abstract] [Full Text] [Related]

  • 20. Live cold-adapted influenza A vaccine produced in Vero cell line.
    Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A.
    Virus Res; 2004 Jul 15; 103(1-2):187-93. PubMed ID: 15163508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.